Multidisciplinary

Top Medical News
Switching from ARB, ACEI to sacubitril/valsartan ups angioedema risk
10 hours ago
New users of sacubitril-valsartan (SV) show no increased risk of angioedema when compared to users of angiotensin-converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB), reports a study.
Early-onset fever tied to severe cytokine release syndrome, multiple tocilizumab doses
11 hours ago
An earlier onset of fever appears to predict a more severe and progressive cytokine release syndrome, a life-threatening hyper-inflammatory state caused by immune effector cell therapy, suggests a study. Such condition also warrants several doses of anti-interleukin (IL)-6 therapy, such as tocilizumab.
Ospemifene improves vaginal microbiome of women with vulvovaginal atrophy
16 hours ago
Women with vulvovaginal atrophy exhibit a less favourable vaginal microbiome than healthy postmenopausal women, but ospemifene may restore vaginal health by reducing potentially harmful bacteria, as shown in a study.
Smoking ups risk of surgical intervention for thyroid eye disease
Yesterday
Smokers with thyroid eye disease are more likely to undergo surgery for their condition compared with their counterparts who do not smoke, a study has found.
Pharmacist-led intervention improves BP control of patients on oral chemotherapy
Yesterday
Patients on oral chemotherapy, who underwent a pharmacist-led hypertension management program, show improvements in blood pressure (BP) control as well as lower mean BP readings over time, reports a recent study.
Diabetes status may influence long-term survival in metastatic breast cancer
Yesterday
A recent study has found an association between diabetes mellitus and higher serum neurofilament light chain (sNfL), biomarkers of neuroaxonal injury in multiple neurological diseases, in a US population.
SAVE-MORE subgroup analysis further reinforces anakinra benefit in COVID-19
Roshini Claire Anthony, 2 days ago

The benefit of anakinra treatment in patients hospitalized with COVID-19 is consistent regardless of age, sex, comorbidities, and suPAR* levels, according to subgroup analysis of the SAVE-MORE trial.

Special Reports
Antimicrobial resistance: Next global, public health threat after COVID-19
Pank Jit Sin, 10 Jan 2023
As the dust settles from the SARS-CoV-2 pandemic, the lurking threat of antimicrobial resistance (AMR) once again rears its ugly head. Weighing in on this topic is Professor Dr Sasheela Sri La Sri Ponnampalavanar, Infectious Disease Professor, University Malaya Medical Centre (UMMC). Below is an excerpt from her bylined piece titled ‘Tackling the Next Global and Public Health Threat After COVID-19 – Antimicrobial Resistance (AMR).’
Simplicity with linagliptin: Efficacy and safety in a broad range
of patients with type 2 diabetes mellitus including those
01 Jan 2023
At a recent webinar jointly organised by the Malaysian Medical Association and Boehringer Ingelheim celebrating a decade-long of linagliptin use in patients with type 2 diabetes mellitus (T2DM), two distinguished speakers addressed the efficacy and safety of linagliptin in a broad range of patients with T2DM; updates from recent clinical trials and real-world evidence were discussed.
Multipathogen testing an essential part of Test-Target-Treat strategy for respiratory illnesses
Dr. Mohan Ravuru, Dr. Johnny Sinon, Assoc Prof. Nuntra Suwantarat, 16 Dec 2022

At a recent webinar, experts discussed the paradigm shift in respiratory illnesses and treatment practices as the COVID-19 pandemic transitions to an endemic phase. The late Dr Mohan Ravuru, Physician Researcher and former Asia Pacific Medical Director, Abbott, Dr Johnny Sinon, Senior Emergency Physician from Makati Medical Center, Philippines, and Associate Professor Nuntra Suwantarat, Infectious Disease Specialist, from Chulabhorn International College of Medicine, Thammasat University, Thailand, delivered informative presentations and engaged the audience through a stimulating panel discussion.

Among the topics covered were the ‘immunity debt’ phenomenon leading to potential epidemics, challenges in the differential diagnosis of COVID-19 and influenza, and the importance of point-of-care, multipathogen testing as a part of the Test-Target-Treat strategy in respiratory diseases.

A retrospective case series of ovarian stimulation
with follitropin delta in a mixed regimen with HP-hMG:
An interim analys
05 Dec 2022
Studies have shown that controlled ovarian stimulation (COS) supplementation with human chorionic gonadotropin (hCG)-driven luteinising hormone activity such as highly purified human menopausal gonadotropin (HP-hMG) (Menopur®) resulted in a significantly higher proportion of top-quality embryos and numbers of good-quality blastocysts compared with recombinant follicle-stimulating hormone (rFSH) alone. Regimens that combine FSH and hMG are often referred to as ‘mixed protocols’ and have been widely used for ovarian stimulation in the past decade. This single-centre, retrospective case series study aims to assess the efficacy of COS with follitropin delta in a mixed protocol regimen with HP-hMG in terms of the number of top-quality embryos and clinical pregnancy rate among Malaysian patients in a reproductive medicine clinic.
MANAGING INFECTIONS AMONG PATIENTS WITH MULTIPLE MYELOMA
05 Dec 2022
Managing infections in patients with multiple myeloma (MM)is important to improve their quality of life. Patients with MM are prone to infections due to the disease itself—the production of many malignant clonal plasma cells, which in turn, produce defective monoclonal antibodies.
Targeting the right patients in treatment of severe eosinophilic asthma and bringing balance to their lives.
05 Dec 2022
In conjunction with World Asthma Day and launch ofmepolizumab, GSK organised a webinar for healthcare professionals titled “The Right Patients at the Right Time: Elevating Care for SEA Patients with Biologics". Associate Professor Dr Mariko Koh Siyue, Senior Consultant in Respiratory and Critical Care Medicine, briefed the audience on severe eosinophilic asthma and discussed two case studies.
New Treatment Options for Multiple Myeloma Improves Patients’ Overall Survival, Quality of Life
05 Dec 2022
Multiple myeloma (MM) is a form of cancer where abnormal plasma cells, a type of white blood cell, accumulate in the bone marrow and replace the normal, healthy cells. While healthy plasma cells produce antibodies, cancerous plasma cells produce abnormal proteins, and the by-products of these proteins cause complications. New treatment options have transformed MM from an acute disease with a median survival of <6 months to a chronic condition where patients have better survival and quality of life (QOL).
Conference Reports
Durable benefits with beti-cel therapy in beta-thalassaemia
Elvira Manzano, 26 Jan 2023
One-time ex-vivo gene therapy with betibeglogene autotemcel (beti-cel) reduces the need for transfusion in patients with transfusion-dependent beta-thalassaemia in an analysis of studies presented at ASH 2022.
Efgartigimod tied to sustained platelet count increase in patients with ITP
Elaine Soliven, 24 Jan 2023
Among patients with chronic or persistent immune thrombocytopenia (ITP), treatment with efgartigimod, a neonatal Fc receptor (FcRn) antagonist, resulted in a higher proportion of patients achieving a sustained platelet count response compared with placebo, according to the ADVANCE IV* trial presented at ASH 2022.
Device filters out direct thrombin inhibitor from plasma for routine haemostasis tests
Jairia Dela Cruz, 23 Jan 2023
A user-friendly medical device can effectively remove the direct thrombin inhibitor (DTI) argatroban from plasma in a rapid and ergonomic manner, as shown in the results of a study presented at ASH 2022.
Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC
Roshini Claire Anthony, 20 Jan 2023

Updated results of the DESTINY-Breast03 trial, presented at SABCS 2022, showed that in patients with HER2+ metastatic breast cancer, second-line treatment with trastuzumab deruxtecan conferred better survival benefits than treatment with trastuzumab emtansine.

FRSW 107 proven safe, effective in previously treated patients with haemophilia A
Stephen Padilla, 20 Jan 2023
Use of FRSW 107, a novel homodimer recombinant factor VIII (rFVIII) Fc fusion protein, for prophylaxis and treatment of bleeding episodes is both safe and effective among previously treated adolescent and adult patients with haemophilia A (HA), reports a China study presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.
Signs of heavy menstrual bleeding often missed; standardized criteria for assessment needed
Jairia Dela Cruz, 20 Jan 2023
Healthcare professionals (HCPs) and women themselves may overlook the signs of heavy menstrual bleeding, with most HCPs failing to recognize the key indicators for bleeding disorders and perform assessments for patients with heavy menstrual bleeding, according to a study presented at ASH 2022.
Mitapivat maintains long-term Hb response in PK deficiency patients
Stephen Padilla, 19 Jan 2023
Treatment with mitapivat results in long-term and durable improvements in haemoglobin (Hb) and a decrease in transfusion burden over several years in patients with pyruvate kinase (PK) deficiency, according to the results of a study, which was presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.